Lyell Immunopharma Inc Forecast, price target & analysts
Lyell Immunopharma Inc Target price 2026 - Analyst rating & recommendation
Lyell Immunopharma Inc Classifications & Recommendation
Lyell Immunopharma Inc Price Target
| Target Price | $42.33 |
| Price | $9.85 |
| Potential |
329.75%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target Lyell Immunopharma Inc 2027 .
The average Lyell Immunopharma Inc target price is $42.33.
This is
329.75%
register free of charge
$51.45
422.34%
register free of charge
$12.12
23.05%
register free of charge
|
|
| A rating was issued by 14 analysts: 12 Analysts recommend Lyell Immunopharma Inc to buy, 1 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Lyell Immunopharma Inc stock has an average upside potential 2027 of
329.75%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.04 | 0.01 |
| 33.33% | 70.50% | |
| EBITDA Margin | -475,225.00% | -1,788,914.36% |
| 42.11% | 276.44% | |
| Net Margin | -686,125.00% | -1,516,141.87% |
| 20.03% | 120.97% |
11 Analysts have issued a sales forecast Lyell Immunopharma Inc 2026 . The average Lyell Immunopharma Inc sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Lyell Immunopharma Inc EBITDA forecast 2026. The average Lyell Immunopharma Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
11 Lyell Immunopharma Inc Analysts have issued a net profit forecast 2026. The average Lyell Immunopharma Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -16.06 | -7.64 |
| 38.77% | 52.43% | |
| P/E | negative | |
| EV/Sales | 3,161.68 |
11 Analysts have issued a Lyell Immunopharma Inc forecast for earnings per share. The average Lyell Immunopharma Inc EPS is
This results in the following potential growth metrics and future valuations:
Lyell Immunopharma Inc...
Current Lyell Immunopharma Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Needham |
Locked
➜
Locked
|
Locked | Sep 11 2026 |
| Stifel |
Locked
➜
Locked
|
Locked | Aug 06 2026 |
| B. Riley Securities |
Locked
➜
Locked
|
Locked | Jul 22 2026 |
| Citizens |
Locked
➜
Locked
|
Locked | Jun 15 2026 |
| Needham |
Locked
➜
Locked
|
Locked | Jun 15 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 09 2026 |
| Needham |
Locked
➜
Locked
|
Locked | Jun 08 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Needham:
Locked
➜
Locked
|
Sep 11 2026 |
|
Locked
Stifel:
Locked
➜
Locked
|
Aug 06 2026 |
|
Locked
B. Riley Securities:
Locked
➜
Locked
|
Jul 22 2026 |
|
Locked
Citizens:
Locked
➜
Locked
|
Jun 15 2026 |
|
Locked
Needham:
Locked
➜
Locked
|
Jun 15 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 09 2026 |
|
Locked
Needham:
Locked
➜
Locked
|
Jun 08 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
